Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 8 (2011), Issue 1 (January)

  1. Adenovirus E2F1 overexpression sensitizes LNCaP and PC3 prostate tumor cells to radiation in vivo.
    Int J Radiat Oncol Biol Phys, 79(2): 549-58. [Abstract] [Full-text]
  2. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy.
    Int J Radiat Oncol Biol Phys, 79(2): 363-70. [Abstract] [Full-text]
  3. α-Methylacyl-CoA racemase spliced variants and their expression in normal and malignant prostate tissues.
    Urology, 77(1): 249.e1-7. [Abstract] [Full-text]
  4. Does PSADT after radical prostatectomy correlate with overall survival?--a report from the SEARCH database group.
    Urology, 77(1): 149-53. [Abstract] [Full-text]
  5. Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells.
    Cancer Lett, 301(1): 17-28. [Abstract] [Full-text]
  6. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer.
    Int J Radiat Oncol Biol Phys, 79(2): 335-41. [Abstract] [Full-text]
  7. Clinical trials of a urethral dose measurement system in brachytherapy using scintillation detectors.
    Int J Radiat Oncol Biol Phys, 79(2): 609-15. [Abstract] [Full-text]
  8. PCA3: from basic molecular science to the clinical lab.
    Cancer Lett, 301(1): 1-6. [Abstract] [Full-text]
  9. Trans-rectal ultrasound-coupled spectral optical tomography of total hemoglobin concentration enhances assessment of the laterality and progression of a transmissible venereal tumor in canine prostate.
    Urology, 77(1): 237-42. [Abstract] [Full-text]
  10. Proton radiotherapy: the biological effect of treating alternating subsets of fields for different treatment fractions.
    Int J Radiat Oncol Biol Phys, 79(2): 616-22. [Abstract] [Full-text]
  11. Dosimetric effect of online image-guided anatomical interventions for postprostatectomy cancer patients.
    Int J Radiat Oncol Biol Phys, 79(2): 623-32. [Abstract] [Full-text]
  12. The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy.
    Int J Radiat Oncol Biol Phys, 79(2): 379-84. [Abstract] [Full-text]
  13. 3D MR-spectroscopic imaging assessment of metabolic activity in the prostate during the PSA "bounce" following 125iodine brachytherapy.
    Int J Radiat Oncol Biol Phys, 79(2): 371-8. [Abstract] [Full-text]
  14. A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial.
    Int J Radiat Oncol Biol Phys, 79(2): 385-91. [Abstract] [Full-text]
  15. Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer.
    J Cancer Res Clin Oncol, 137(1): 19-28. [Abstract] [Full-text]
  16. Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids.
    Cancer Chemother Pharmacol, 67(1): 117-26. [Abstract] [Full-text]
  17. Adenovirus E2F1 overexpression sensitizes LNCaP and PC3 prostate tumor cells to radiation in vivo.
    Int J Radiat Oncol Biol Phys, 79(2): 549-58. [Abstract] [Full-text]
  18. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy.
    Int J Radiat Oncol Biol Phys, 79(2): 363-70. [Abstract] [Full-text]
  19. Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells.
    Cancer Lett, 301(1): 17-28. [Abstract] [Full-text]
  20. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer.
    Int J Radiat Oncol Biol Phys, 79(2): 335-41. [Abstract] [Full-text]
  21. Clinical trials of a urethral dose measurement system in brachytherapy using scintillation detectors.
    Int J Radiat Oncol Biol Phys, 79(2): 609-15. [Abstract] [Full-text]
  22. PCA3: from basic molecular science to the clinical lab.
    Cancer Lett, 301(1): 1-6. [Abstract] [Full-text]
  23. The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population.
    Exp Mol Pathol, 90(1): 97-100. [Abstract] [Full-text]
  24. Proton radiotherapy: the biological effect of treating alternating subsets of fields for different treatment fractions.
    Int J Radiat Oncol Biol Phys, 79(2): 616-22. [Abstract] [Full-text]
  25. Dosimetric effect of online image-guided anatomical interventions for postprostatectomy cancer patients.
    Int J Radiat Oncol Biol Phys, 79(2): 623-32. [Abstract] [Full-text]
  26. The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy.
    Int J Radiat Oncol Biol Phys, 79(2): 379-84. [Abstract] [Full-text]
  27. 3D MR-spectroscopic imaging assessment of metabolic activity in the prostate during the PSA "bounce" following 125iodine brachytherapy.
    Int J Radiat Oncol Biol Phys, 79(2): 371-8. [Abstract] [Full-text]
  28. A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial.
    Int J Radiat Oncol Biol Phys, 79(2): 385-91. [Abstract] [Full-text]
  29. Adenovirus E2F1 overexpression sensitizes LNCaP and PC3 prostate tumor cells to radiation in vivo.
    Int J Radiat Oncol Biol Phys, 79(2): 549-58. [Abstract] [Full-text]
  30. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy.
    Int J Radiat Oncol Biol Phys, 79(2): 363-70. [Abstract] [Full-text]
  31. Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells.
    Cancer Lett, 301(1): 17-28. [Abstract] [Full-text]
  32. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer.
    Int J Radiat Oncol Biol Phys, 79(2): 335-41. [Abstract] [Full-text]
  33. Clinical trials of a urethral dose measurement system in brachytherapy using scintillation detectors.
    Int J Radiat Oncol Biol Phys, 79(2): 609-15. [Abstract] [Full-text]
  34. PCA3: from basic molecular science to the clinical lab.
    Cancer Lett, 301(1): 1-6. [Abstract] [Full-text]
  35. The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population.
    Exp Mol Pathol, 90(1): 97-100. [Abstract] [Full-text]
  36. Proton radiotherapy: the biological effect of treating alternating subsets of fields for different treatment fractions.
    Int J Radiat Oncol Biol Phys, 79(2): 616-22. [Abstract] [Full-text]
  37. Dosimetric effect of online image-guided anatomical interventions for postprostatectomy cancer patients.
    Int J Radiat Oncol Biol Phys, 79(2): 623-32. [Abstract] [Full-text]
  38. The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy.
    Int J Radiat Oncol Biol Phys, 79(2): 379-84. [Abstract] [Full-text]
  39. 3D MR-spectroscopic imaging assessment of metabolic activity in the prostate during the PSA "bounce" following 125iodine brachytherapy.
    Int J Radiat Oncol Biol Phys, 79(2): 371-8. [Abstract] [Full-text]
  40. A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial.
    Int J Radiat Oncol Biol Phys, 79(2): 385-91. [Abstract] [Full-text]
  41. Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors Committee.
    Int J Cancer, 128(5): 1232-9. [Abstract] [Full-text]
  42. Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors Committee.
    Int J Cancer, 128(5): 1232-9. [Abstract] [Full-text]
  43. Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors Committee.
    Int J Cancer, 128(5): 1232-9. [Abstract] [Full-text]
  44. Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer.
    J Clin Endocrinol Metab, 96(1): E135-40. [Abstract] [Full-text]
  45. Impact of age at diagnosis on prostate cancer treatment and survival.
    J Clin Oncol, 29(2): 235-41. [Abstract] [Full-text]
  46. Outcomes of active surveillance for men with intermediate-risk prostate cancer.
    J Clin Oncol, 29(2): 228-34. [Abstract] [Full-text]
  47. E2f binding-deficient Rb1 protein suppresses prostate tumor progression in vivo.
    Proc Natl Acad Sci U S A, 108(2): 704-9. [Abstract] [Full-text]
  48. 3,3'-Diindolylmethane inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate model.
    Mol Carcinog, 50(2): 100-12. [Abstract] [Full-text]
  49. Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression.
    J Urol, 185(2): 706-11. [Abstract] [Full-text]
  50. Single focus prostate cancer: pathological features and ERG fusion status.
    J Urol, 185(2): 489-94. [Abstract] [Full-text]
  51. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer.
    J Urol, 185(2): 477-82. [Abstract] [Full-text]
  52. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy.
    J Urol, 185(2): 495-500. [Abstract] [Full-text]
  53. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.
    J Urol, 185(2): 471-6. [Abstract] [Full-text]
  54. The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients.
    J Urol, 185(2): 483-7. [Abstract] [Full-text]
  55. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation.
    Oncogene, 30(2): 142-52. [Abstract] [Full-text]
  56. Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness.
    Oncogene, 30(2): 167-77. [Abstract] [Full-text]
  57. 3,3'-Diindolylmethane inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate model.
    Mol Carcinog, 50(2): 100-12. [Abstract] [Full-text]
  58. Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression.
    J Urol, 185(2): 706-11. [Abstract] [Full-text]
  59. Single focus prostate cancer: pathological features and ERG fusion status.
    J Urol, 185(2): 489-94. [Abstract] [Full-text]
  60. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer.
    J Urol, 185(2): 477-82. [Abstract] [Full-text]
  61. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy.
    J Urol, 185(2): 495-500. [Abstract] [Full-text]
  62. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.
    J Urol, 185(2): 471-6. [Abstract] [Full-text]
  63. The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients.
    J Urol, 185(2): 483-7. [Abstract] [Full-text]
  64. Synergistic antimicrotubule therapy for prostate cancer.
    Biochem Pharmacol, 81(4): 478-87. [Abstract] [Full-text]
  65. Synergistic antimicrotubule therapy for prostate cancer.
    Biochem Pharmacol, 81(4): 478-87. [Abstract] [Full-text]
  66. Low-grade fibromyxoid sarcoma metastatic to the prostate.
    Ann Diagn Pathol, 15(1): 64-8. [Abstract] [Full-text]
  67. Synergistic antimicrotubule therapy for prostate cancer.
    Biochem Pharmacol, 81(4): 478-87. [Abstract] [Full-text]
  68. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression.
    J Pharmacol Exp Ther, 336(2): 496-505. [Abstract] [Full-text]
  69. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy.
    Prostate, 71(3): 326-31. [Abstract] [Full-text]
  70. Expression of pleiotrophin in the prostate is androgen regulated and it functions as an autocrine regulator of mesenchyme and cancer associated fibroblasts and as a paracrine regulator of epithelia.
    Prostate, 71(3): 305-17. [Abstract] [Full-text]
  71. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.
    Prostate, 71(3): 281-8. [Abstract] [Full-text]
  72. Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior.
    Prostate, 71(3): 318-25. [Abstract] [Full-text]
  73. Targeting prostate cancer angiogenesis through metastasis-associated protein 1 (MTA1).
    Prostate, 71(3): 268-80. [Abstract] [Full-text]
  74. Evidence for an association between prostate cancer and chromosome 8q24 and 10q11 genetic variants in African American men: the Flint Men's Health Study.
    Prostate, 71(3): 225-31. [Abstract] [Full-text]
  75. Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells.
    Prostate, 71(3): 298-304. [Abstract] [Full-text]
  76. Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy.
    Prostate, 71(3): 232-40. [Abstract] [Full-text]
  77. Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence.
    Cancer Immunol Immunother, 60(2): 217-26. [Abstract] [Full-text]
  78. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination.
    Cancer Immunol Immunother, 60(2): 197-206. [Abstract] [Full-text]
  79. Natural antibodies against nerve growth factor inhibit in vitro prostate cancer cell metastasis.
    Cancer Immunol Immunother, 60(2): 187-95. [Abstract] [Full-text]
  80. Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer.
    Prostate, 71(4): 421-30. [Abstract] [Full-text]
  81. Prevalence of human xenotropic murine leukemia virus-related gammaretrovirus (XMRV) in Dutch prostate cancer patients.
    Prostate, 71(4): 415-20. [Abstract] [Full-text]
  82. Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a "normal" prostate specific antigen and digital rectal examination.
    Prostate, 71(4): 394-402. [Abstract] [Full-text]
  83. Transcriptional coactivators p300 and CBP stimulate estrogen receptor-beta signaling and regulate cellular events in prostate cancer.
    Prostate, 71(4): 431-7. [Abstract] [Full-text]
  84. ETS1 regulates NKX3.1 5' promoter activity and expression in prostate cancer cells.
    Prostate, 71(4): 403-14. [Abstract] [Full-text]
  85. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy.
    Prostate, 71(3): 326-31. [Abstract] [Full-text]
  86. Prostatectomy restores the maturation competence of blood dendritic cell precursors and reverses the abnormal expansion of regulatory T lymphocytes.
    Prostate, 71(4): 344-52. [Abstract] [Full-text]
  87. Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients.
    Prostate, 71(4): 368-72. [Abstract] [Full-text]
  88. Cell-cycle regulators cdk2ap1 and bicalutamide suppress malignant biological interactions between prostate cancer and bone cells.
    Prostate, 71(4): 353-67. [Abstract] [Full-text]
  89. Tumor cell group via phospholipase A₂ is involved in prostate cancer development.
    Prostate, 71(4): 373-84. [Abstract] [Full-text]
  90. Significant prognostic factor of immunohistochemical HER-2 expression using initial prostate biopsy specimens with M1b prostate cancer.
    Prostate, 71(4): 385-93. [Abstract] [Full-text]
  91. Expression of pleiotrophin in the prostate is androgen regulated and it functions as an autocrine regulator of mesenchyme and cancer associated fibroblasts and as a paracrine regulator of epithelia.
    Prostate, 71(3): 305-17. [Abstract] [Full-text]
  92. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.
    Prostate, 71(3): 281-8. [Abstract] [Full-text]
  93. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth.
    Prostate, 71(4): 333-43. [Abstract] [Full-text]
  94. Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior.
    Prostate, 71(3): 318-25. [Abstract] [Full-text]
  95. Targeting prostate cancer angiogenesis through metastasis-associated protein 1 (MTA1).
    Prostate, 71(3): 268-80. [Abstract] [Full-text]
  96. Evidence for an association between prostate cancer and chromosome 8q24 and 10q11 genetic variants in African American men: the Flint Men's Health Study.
    Prostate, 71(3): 225-31. [Abstract] [Full-text]
  97. Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells.
    Prostate, 71(3): 298-304. [Abstract] [Full-text]
  98. Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy.
    Prostate, 71(3): 232-40. [Abstract] [Full-text]
  99. Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer.
    Prostate, 71(4): 421-30. [Abstract] [Full-text]
  100. Prevalence of human xenotropic murine leukemia virus-related gammaretrovirus (XMRV) in Dutch prostate cancer patients.
    Prostate, 71(4): 415-20. [Abstract] [Full-text]
  101. Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a "normal" prostate specific antigen and digital rectal examination.
    Prostate, 71(4): 394-402. [Abstract] [Full-text]
  102. Transcriptional coactivators p300 and CBP stimulate estrogen receptor-beta signaling and regulate cellular events in prostate cancer.
    Prostate, 71(4): 431-7. [Abstract] [Full-text]
  103. ETS1 regulates NKX3.1 5' promoter activity and expression in prostate cancer cells.
    Prostate, 71(4): 403-14. [Abstract] [Full-text]
  104. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy.
    Prostate, 71(3): 326-31. [Abstract] [Full-text]
  105. Prostatectomy restores the maturation competence of blood dendritic cell precursors and reverses the abnormal expansion of regulatory T lymphocytes.
    Prostate, 71(4): 344-52. [Abstract] [Full-text]
  106. Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients.
    Prostate, 71(4): 368-72. [Abstract] [Full-text]
  107. Cell-cycle regulators cdk2ap1 and bicalutamide suppress malignant biological interactions between prostate cancer and bone cells.
    Prostate, 71(4): 353-67. [Abstract] [Full-text]
  108. Tumor cell group via phospholipase A₂ is involved in prostate cancer development.
    Prostate, 71(4): 373-84. [Abstract] [Full-text]
  109. Significant prognostic factor of immunohistochemical HER-2 expression using initial prostate biopsy specimens with M1b prostate cancer.
    Prostate, 71(4): 385-93. [Abstract] [Full-text]
  110. Expression of pleiotrophin in the prostate is androgen regulated and it functions as an autocrine regulator of mesenchyme and cancer associated fibroblasts and as a paracrine regulator of epithelia.
    Prostate, 71(3): 305-17. [Abstract] [Full-text]
  111. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.
    Prostate, 71(3): 281-8. [Abstract] [Full-text]
  112. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth.
    Prostate, 71(4): 333-43. [Abstract] [Full-text]
  113. Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior.
    Prostate, 71(3): 318-25. [Abstract] [Full-text]
  114. Targeting prostate cancer angiogenesis through metastasis-associated protein 1 (MTA1).
    Prostate, 71(3): 268-80. [Abstract] [Full-text]
  115. Evidence for an association between prostate cancer and chromosome 8q24 and 10q11 genetic variants in African American men: the Flint Men's Health Study.
    Prostate, 71(3): 225-31. [Abstract] [Full-text]
  116. Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells.
    Prostate, 71(3): 298-304. [Abstract] [Full-text]
  117. Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy.
    Prostate, 71(3): 232-40. [Abstract] [Full-text]
  118. Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer.
    Prostate, 71(4): 421-30. [Abstract] [Full-text]
  119. Prevalence of human xenotropic murine leukemia virus-related gammaretrovirus (XMRV) in Dutch prostate cancer patients.
    Prostate, 71(4): 415-20. [Abstract] [Full-text]
  120. Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a "normal" prostate specific antigen and digital rectal examination.
    Prostate, 71(4): 394-402. [Abstract] [Full-text]
  121. Transcriptional coactivators p300 and CBP stimulate estrogen receptor-beta signaling and regulate cellular events in prostate cancer.
    Prostate, 71(4): 431-7. [Abstract] [Full-text]
  122. ETS1 regulates NKX3.1 5' promoter activity and expression in prostate cancer cells.
    Prostate, 71(4): 403-14. [Abstract] [Full-text]
  123. Prostatectomy restores the maturation competence of blood dendritic cell precursors and reverses the abnormal expansion of regulatory T lymphocytes.
    Prostate, 71(4): 344-52. [Abstract] [Full-text]
  124. Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients.
    Prostate, 71(4): 368-72. [Abstract] [Full-text]
  125. Cell-cycle regulators cdk2ap1 and bicalutamide suppress malignant biological interactions between prostate cancer and bone cells.
    Prostate, 71(4): 353-67. [Abstract] [Full-text]
  126. Tumor cell group via phospholipase A₂ is involved in prostate cancer development.
    Prostate, 71(4): 373-84. [Abstract] [Full-text]
  127. Significant prognostic factor of immunohistochemical HER-2 expression using initial prostate biopsy specimens with M1b prostate cancer.
    Prostate, 71(4): 385-93. [Abstract] [Full-text]
  128. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth.
    Prostate, 71(4): 333-43. [Abstract] [Full-text]
  129. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy.
    AJR Am J Roentgenol, 196(2): 374-81. [Abstract] [Full-text]
  130. Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase.
    J Biol Chem, 286(4): 2681-8. [Abstract] [Full-text]
  131. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
    BJU Int, 107(3): 383-8. [Abstract] [Full-text]
  132. High-intensity focused ultrasound as salvage therapy for patients with recurrent prostate cancer after external beam radiation, brachytherapy or proton therapy.
    BJU Int, 107(3): 378-82. [Abstract] [Full-text]
  133. Testosterone augments polyphenol-induced DNA damage response in prostate cancer cell line, LNCaP.
    Cancer Sci, 102(2): 468-71. [Abstract] [Full-text]
  134. Influence of caspases 8 and 9 gene promoter polymorphism on prostate cancer susceptibility and early development of hormone refractory prostate cancer.
    BJU Int, 107(3): 471-6. [Abstract] [Full-text]
  135. Clinical significance of runt-related transcription factor 1 polymorphism in prostate cancer.
    BJU Int, 107(3): 486-92. [Abstract] [Full-text]
  136. Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val.
    BJU Int, 107(3): 466-70. [Abstract] [Full-text]
  137. A post-radical-prostatectomy nomogram incorporating new pathological variables and interaction terms for improved prognosis.
    BJU Int, 107(3): 389-95. [Abstract] [Full-text]
  138. 'LESS' radical prostatectomy: a pilot feasibility study with a personal original technique.
    BJU Int, 107(3): 460-4. [Abstract] [Full-text]
  139. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
    BJU Int, 107(3): 477-85. [Abstract] [Full-text]
  140. ACR appropriateness criteria postradical prostatectomy irradiation in prostate cancer.
    Am J Clin Oncol, 34(1): 92-8. [Abstract] [Full-text]
  141. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors.
    J Nucl Med, 52(2): 270-8. [Abstract] [Full-text]
  142. Evaluation of kV cone-beam ct performance for prostate IGRT: a comparison of automatic grey-value alignment to implanted fiducial-marker alignment.
    Am J Clin Oncol, 34(1): 16-21. [Abstract] [Full-text]
  143. Androgen deprivation induces rapid involution and recovery of human prostate vasculature.
    Am J Physiol Endocrinol Metab, 300(2): E263-75. [Abstract] [Full-text]
  144. Toxicity analysis of dose escalation from 75.6 gy to 81.0 gy in prostate cancer.
    Am J Clin Oncol, 34(1): 11-5. [Abstract] [Full-text]
  145. Acute toxicity after cyberknife-delivered hypofractionated radiotherapy for treatment of prostate cancer.
    Am J Clin Oncol, 34(1): 6-10. [Abstract] [Full-text]
  146. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing?
    J Clin Oncol, 29(4): 464-7. [Abstract] [Full-text]
  147. Involvement of HDAC1 in E-cadherin expression in prostate cancer cells; its implication for cell motility and invasion.
    Biochem Biophys Res Commun, 404(4): 915-21. [Abstract] [Full-text]
  148. BTG2 is an LXXLL-dependent co-repressor for androgen receptor transcriptional activity.
    Biochem Biophys Res Commun, 404(4): 903-9. [Abstract] [Full-text]
  149. Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial.
    J Clin Oncol, 29(4): 362-8. [Abstract] [Full-text]
  150. Comorbidity and mortality results from a randomized prostate cancer screening trial.
    J Clin Oncol, 29(4): 355-61. [Abstract] [Full-text]
  151. Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).
    Int J Cancer, 128(6): 1442-8. [Abstract] [Full-text]
  152. PSA-detected prostate cancer and the potential for dedifferentiation--estimating the proportion capable of progression.
    Int J Cancer, 128(6): 1462-70. [Abstract] [Full-text]
  153. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy.
    Int J Cancer, 128(6): 1486-92. [Abstract] [Full-text]
  154. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma.
    Int J Cancer, 128(6): 1414-24. [Abstract] [Full-text]
  155. Adjuvant radiotherapy after radical prostatectomy: evidence and analysis.
    Cancer Treat Rev, 37(2): 89-96. [Abstract] [Full-text]
  156. Surgery confounds biology: the predictive value of stage-, grade- and prostate-specific antigen for recurrence after radical prostatectomy as a function of surgeon experience.
    Int J Cancer, 128(7): 1697-702. [Abstract] [Full-text]
  157. Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).
    Int J Cancer, 128(6): 1442-8. [Abstract] [Full-text]
  158. PSA-detected prostate cancer and the potential for dedifferentiation--estimating the proportion capable of progression.
    Int J Cancer, 128(6): 1462-70. [Abstract] [Full-text]
  159. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy.
    Int J Cancer, 128(6): 1486-92. [Abstract] [Full-text]
  160. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma.
    Int J Cancer, 128(6): 1414-24. [Abstract] [Full-text]
  161. Adjuvant radiotherapy after radical prostatectomy: evidence and analysis.
    Cancer Treat Rev, 37(2): 89-96. [Abstract] [Full-text]
  162. Surgery confounds biology: the predictive value of stage-, grade- and prostate-specific antigen for recurrence after radical prostatectomy as a function of surgeon experience.
    Int J Cancer, 128(7): 1697-702. [Abstract] [Full-text]
  163. Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).
    Int J Cancer, 128(6): 1442-8. [Abstract] [Full-text]
  164. PSA-detected prostate cancer and the potential for dedifferentiation--estimating the proportion capable of progression.
    Int J Cancer, 128(6): 1462-70. [Abstract] [Full-text]
  165. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy.
    Int J Cancer, 128(6): 1486-92. [Abstract] [Full-text]
  166. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma.
    Int J Cancer, 128(6): 1414-24. [Abstract] [Full-text]
  167. Adjuvant radiotherapy after radical prostatectomy: evidence and analysis.
    Cancer Treat Rev, 37(2): 89-96. [Abstract] [Full-text]
  168. Surgery confounds biology: the predictive value of stage-, grade- and prostate-specific antigen for recurrence after radical prostatectomy as a function of surgeon experience.
    Int J Cancer, 128(7): 1697-702. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

What Your Doctor May Not Tell You About(TM) Prostate Cancer: The Breakthrough Information and Treatments That Can Help Save Your Life (What Your Doctor May Not Tell You About...)

What Your Doctor May Not Tell You About(TM) Prostate Cancer: The Breakthrough Information and Treatments That Can Help Save Your Life (What Your Doctor May Not Tell You About...)